Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol

References

• Chronic obstructive pulmonary disease (COPD) fact sheet [webpage on the Internet]Washington DCAmerican Lung Association2011 Available from: http://www.lung.org/lung-disease/copd/resources/facts-figures/COPD-Fact-Sheet.htmlAccessed September 14, 2012
   Google Scholar
• National Clinical Guideline CenterChronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary CareLondonNational Clinical Guideline Center2010 Available from: http://guidance.nice.org.uk/CG101/Guidance/pdf/EnglishAccessed November 14, 2012
   Google Scholar
• JonesPWAgustiAGOutcomes and markers in the assessment of chronic obstructive pulmonary diseaseEur Respir J200627482283216585091
   PubMed Web of Science ®Google Scholar
• CazzolaMMacNeeWMartinezFJAmerican Thoracic Society; European Respiratory Society Task Force on outcomes of COPDOutcomes for COPD pharmacological trials: from lung function to biomakersEur Respir J200831241646918238951
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionMeasuring Healthy Days: Population Assessment of Health-Related Quality of LifeAtlanta, GACenters for Disease Control and Prevention2000 Available from: http://www.cdc.gov/hrqol/pdfs/mhd.pdfAccessed November 14, 2012
   Google Scholar
• BullingerMAndersonRCellaDAaronsonNDeveloping and evaluating cross-cultural instruments from minimum requirements to optimal modelsQual Life Res1993264514598161979
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseGOLD; revised2011 Available from: http://www.Goldcopd.comAccessed September 14, 2012
   Google Scholar
• MahlerDAHow should health-related quality of life be assessed in patients with COPD?Chest2000117Suppl 2S54S57
   Web of Science ®Google Scholar
• ReardonJZLareauSCZuWallackRFunctional status and quality of life in chronic obstructive pulmonary diseaseAm J Med200611910 Suppl 1323716996897
   PubMed Web of Science ®Google Scholar
• Martín A, Rodríguez-González Moro JM, Izquierdo JL, Gobartt E, de Lucas P; VICE Study Group. Health-related quality of life in outpatients with COPD in daily practice: the VICE Spanish studyInt J Chron Obstruct Pulmon Dis20083468369219283915
   PubMedGoogle Scholar
• TsiligianniIKocksJTzanakisNSiafakasNvan der MolenTFactors that infuence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlationsPrim Care Respir J201120325726821472192
   PubMedGoogle Scholar
• JonesPWQuirkFHBaveystockCMLittlejohnsPA self-complete measure of health status for chronic airflow limitation: the St George’s Respiratory QuestionnaireAm Rev Respir Dis19921456132113271595997
   PubMed Web of Science ®Google Scholar
• FeldmanGSilerTPrasadNINLIGHT-1study groupEfficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week studyBMC Pulm Med2010101120211002
   PubMed Web of Science ®Google Scholar
• KornmannODahlRCentanniSINLIGHT-2 study investigatorsOnce-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparisonEur Respir J201137227327920693243
   PubMed Web of Science ®Google Scholar
• DahlRChungKFBuhlRINVOLVE study investigatorsEfficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPDThorax201065647347920522841
   PubMed Web of Science ®Google Scholar
• DonohueJFFogartyCLötvallJHANCE study investigatorsOnce-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumAm J Respir Crit Care Med2010182215516220463178
   PubMed Web of Science ®Google Scholar
• BuhlRDunnLJDisdierCINTENSITY study investigatorsBlinded 12-week comparison of once-daily indacaterol and tiotropium in COPDEur Respir J201138479780321622587
   PubMed Web of Science ®Google Scholar
• KornSKerwinEAtisSAmosCOwenRLassenCINSIST study groupIndacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week studyRespir Med2011105571972621367594
   PubMed Web of Science ®Google Scholar
• ChapmanKRRennardSIDograAOwenRLassenCKramerBINDORSE study investigatorsLong-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled studyChest20111401687521349928
   PubMed Web of Science ®Google Scholar
• VA Pharmacy Benefits Management Services, Medical Advisory Panel, VISN Pharmacist ExecutivesIndacaterol (Arcapta™ Neohaler™): National Drug MonographWashington DCUS Department of Veterans Affairs2012 Available from: http://www.pbm.va.gov/Clinical%20Guidance/drug%20Monographs/Indacaterol.pdfAccessed November 14, 2012
   Google Scholar
• ChowdhuryBASeymourSMMicheleTMDurmowiczAGLiuDRosebraughCJThe risks and benefits of indacaterol: the FDA’s reviewN Engl J Med2011365242247224922168640
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationIndacaterol FDA Summary Review Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000SumR.pdfAccessedFebuary 2 2013
   Google Scholar
• RodrigoGJNeffenHComparison of indacaterol with tiotropium or twice-daily long-acting beta-agonists for stable COPD: a systematic reviewCHEST201214251104111022383666
   PubMed Web of Science ®Google Scholar
• MahlerDAWitekTJJrThe MCID of the transition dyspnea index is a total score of one unitCOPD2005219910317136969
   PubMedGoogle Scholar
• WitekTJJrMahlerDAMinimal important difference of the transition dyspnoea index in a multinational clinical trialEur Respir J200321226727212608440
   PubMed Web of Science ®Google Scholar
• MahlerDAWardJWatermanLAMcCuskerCZuwallackRBairdJCPatient-reported dyspnea in COPD reliability and association with stage of diseaseChest200913661473147919696126
   PubMed Web of Science ®Google Scholar
• JonesPWBarnesNVogelmeierCLawrenceDKramerBEfficacy of indacaterol in the treatment of patients with COPDPrim Care Respir J201120438038821785813
   PubMedGoogle Scholar
• SilerTMWilliamsJYegenUOwenRLassenCKramerBThe effect of once-daily indacaterol on health-related quality of life, rescue medication use, and exacerbation rates in patients with moderate-to-severe COPD: a pooled analysis of three months of treatmentAm J Respir Crit Care Med2010181A4430
   Google Scholar
• KleerupEWilliamsJYegenUOwenRLassenCKramerBThe effect of indacaterol once-daily on health-related quality of life, symptoms and rescue medication use in moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of six monthAm J Respir Crit Care Med2010181A4429
   Google Scholar
• La PianaGECordaLBertellaETaranto MontemurroLPiniLTantucciCDose-responsive curve to salbutamol during acute and chronic treatment with formoterol in COPDInt J Chron Obstruct Pulmon Dis2011639940521857779
   PubMed Web of Science ®Google Scholar
• JonesPWQuirkFHBaveystockCMThe St George’s Respiratory QuestionnaireRespir Med199185Suppl B25311759018
   PubMed Web of Science ®Google Scholar
• JonesPWHealth status measurement in chronic obstructive pulmonary diseaseThorax2001561188088711641515
   PubMed Web of Science ®Google Scholar
• JonesPWInterpreting thresholds for a clinically significant change in health status in asthma and COPDEur Respir J200219339840411936514
   PubMed Web of Science ®Google Scholar
• EstebanCQuintanaJMAburtoMImpact of changes in physical activity on health-related quality of life among patients with COPDEur Respir J201036229230020075059
   PubMed Web of Science ®Google Scholar
• PalangePWardSACarlsenKHERS Task ForceRecommendations on the use of exercise testing in clinical practiceEur Respir J200729118520917197484
   PubMed Web of Science ®Google Scholar
• O’DonnellDECasaburiRVinckenWINABLE 1study groupEffect of indacaterol on exercise endurance and lung hyperinflation in COPDRespir Med201110571030103621498063
   PubMed Web of Science ®Google Scholar
• MrozRMMinarowskiLChyczewskaEIndacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patientsAdv Exp Med Biol2013756232822836615
   PubMed Web of Science ®Google Scholar
• GlaabTVogelmeierCBuhlROutcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitationsRespir Res2010117920565728
   PubMed Web of Science ®Google Scholar
• AnzuetoASethiSMartinezFJExacerbations of chronic obstructive pulmonary diseaseProc Am Thorac Soc20074755456417878469
   PubMedGoogle Scholar
• BurgeSWedzichaJACOPD exacerbations: definitions and classificationsEur Respir J Suppl200341S46S53
   PubMedGoogle Scholar
• PartridgeMRMiravitllesMStåhlEKarlssonNSvenssonKWelteTDevelopment and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPDEur Respir J20103619610419897551
   PubMed Web of Science ®Google Scholar
• MahlerDABuhlRLawrenceDMcBryanDEffectiveness of indacaterol and tiotropium in patients with severe dyspneaEuropean Respiratory Society CongressSeptember 1–5, 2012Vienna, Austria ERS abstract 850630, session 245
   Google Scholar
• MahlerDAD’UrzoAPeckittCLassenCKramerBFilcekSConcurrent Use of Indacaterol Plus Tiotropium in Patients with COPD Provides Superior Bronchodilation Compared with Tiotropium AloneThorax201267978178822544891
   PubMed Web of Science ®Google Scholar
• BatemanEFergusonGTBarnesNBenefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE studyEuropean Respiratory Society CongressSeptember 1–5, 2012Vienna, Austria ERS abstract 700179, session 306
   Google Scholar